Convulsion rx
seizure management treatment guidelines
| Drug | Dose | Route | Notes |
|---|---|---|---|
| Lorazepam | 2-4 mg (adults); repeat once | IV | Preferred if IV access available; onset ~2-3 min, duration 12-24 h |
| Midazolam | 10 mg (adults >40 kg) | IM | Preferred if no IV access; non-inferior to IV lorazepam in trials; also intranasal option |
| Diazepam | 5-10 mg IV; or 0.2-0.5 mg/kg rectal gel | IV / PR | Shorter effective duration (15-60 min) due to rapid redistribution; used if lorazepam/midazolam unavailable |
| Buccal midazolam | 0.5 mg/kg up to 10 mg | Buccal | Superior to rectal diazepam in children |
| Drug | Dose | Route | Notes |
|---|---|---|---|
| Fosphenytoin | 20 PE/kg at 150 PE/min | IV / IM | Preferred over phenytoin - water-soluble, fewer infusion-site reactions; can give IM |
| Phenytoin | 20 mg/kg at ≤50 mg/min | IV | Cardiac monitoring required; risk of hypotension + arrhythmia |
| Levetiracetam | 60 mg/kg (max 4500 mg) | IV | Well tolerated; no cardiac effects |
| Valproate | 40 mg/kg at 6 mg/kg/min | IV | Avoid in known mitochondrial disease, liver disease, pregnancy |
| Lacosamide | 200-400 mg | IV | ECG monitoring required (prolongs PR interval, risk of arrhythmia) |
| Phenobarbital | 20 mg/kg at 50-100 mg/min | IV | Highly effective but causes prolonged sedation, respiratory depression, hypotension |
| Drug | Notes |
|---|---|
| Pentobarbital (anesthetic dose) | IV continuous infusion; titrate to burst suppression on EEG |
| Propofol | IV continuous infusion; risk of propofol infusion syndrome with prolonged use |
| Midazolam | IV continuous infusion |
| Ketamine | Emerging option in super-refractory SE |
| Scenario | Treatment |
|---|---|
| Eclampsia | IV/IM magnesium sulfate (4 g IV loading dose) - drug of choice |
| Alcohol withdrawal | Benzodiazepines first-line; phenobarbital adjunct |
| Hypoglycemia-induced | IV dextrose alone may terminate seizure |
| Hyponatremia-induced | Hypertonic saline |
| Febrile convulsion (child) | Rectal diazepam / buccal midazolam acutely; usually self-limiting |
| Isoniazid toxicity | IV pyridoxine (B6) - gram for gram match to INH dose |
| TCA/cocaine overdose | IV sodium bicarbonate; avoid phenytoin |
| Seizure Type | First-Line AEDs |
|---|---|
| Focal (partial) | Carbamazepine, oxcarbazepine, lamotrigine, levetiracetam, lacosamide |
| Generalized tonic-clonic | Valproate, levetiracetam, lamotrigine |
| Absence | Ethosuximide, valproate, lamotrigine |
| Juvenile myoclonic epilepsy | Valproate, levetiracetam, lamotrigine |
Recent evidence note: A 2024 systematic review of clinical practice guidelines for SE management in adults (PMID 38606469, Epilepsia) confirms that no single second-line agent (levetiracetam vs. valproate vs. fosphenytoin) has demonstrated superiority, consistent with what the textbooks state above.
Create a quick reference PDF of convulsion doses and timings for emergency settings
Convulsion Quick Reference
PDF Document · PDF
| Section | Content |
|---|---|
| Timeline bar | Visual 4-phase strip: 0-5 min → 5-20 min → 20-40 min → >40 min |
| Phase 1 - Benzodiazepines | Lorazepam, midazolam, diazepam, clonazepam - doses, routes, onset, duration |
| Phase 2 - Second-line AEDs | Fosphenytoin, phenytoin, levetiracetam, valproate, lacosamide, phenobarbital - loading doses + infusion rates |
| Phase 3 - Refractory SE | Pentobarbital, propofol, midazolam, ketamine - induction + maintenance doses |
| Special situations | Eclampsia, hypoglycaemia, alcohol withdrawal, INH toxicity, febrile convulsion, hyponatraemia, TCA OD |
| Immediate actions + monitoring | Side-by-side checklist boxes |
| Footer | Source citations + disclaimer |